Skip to main content
SpringerLink
Log in

Cyclophosphamide in steroid-dependent nephrotic syndrome

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

In order to determine the long-term effects of cyclophosphamide (CPO) and to identify parameters associated with sustained remission, we retrospectively studied the data from 90 patients with steroid-dependent nephrotic syndrome (SDNS) who received a single course of oral cyclophosphamide (2 mg/kg/day for 10 to 12 weeks). The median follow-up period after CPO was 5.5 years (interquartile range 3.2–8.5). Sustained remission reached the cumulative rate of 57% at 1 year, 42% at 2 years, and 31% at 5 years. For the patients who relapsed, the median threshold dose of prednisone between CPO initiation and first relapse has significantly decreased (22.1 mg/kg/day versus 4.9 mg/kg/day, p < 0.001). No further immunosuppressive agent was required in 60% of all patients. Young age at CPO initiation was associated with a lower rate of sustained remission (p < 0.001). Age at diagnosis of nephrotic syndrome, gender, cumulative dose of CPO (in mg/kg), and level of steroid dependence at CPO initiation did not influence the outcome. The incidence of side effects was low. These findings suggest that despite the wide use of new immunosuppressive agents, a short course of CPO remains an effective second-line therapy in SDNS patients. Optimal efficiency was observed in children over 7.5 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hodson EM, Willis NS, Craig JC (2008) Non-corticosteroid treatment for nephrotic syndrome in children. Cochrane Database Syst Rev CD002290

  2. Latta K, von Schnakenburg C, Ehrich JH (2001) A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 16:271–282

    Article  CAS  Google Scholar 

  3. Takeda A, Ohgushi H, Niimura F, Matsutani H (1998) Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome. Pediatr Nephrol 12:746–750

    Article  CAS  Google Scholar 

  4. Barratt TM, Bercowsky A, Osofsky SG, Soothill JF (1975) Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood. Lancet 1:55–58

    Article  CAS  Google Scholar 

  5. Arbeitsgemeinschaft für Pädiatrische Nephrologie (1987) Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 62:1102–1106

    Article  Google Scholar 

  6. Shohet I, Meyerovitch J, Aladjem M, Boichis H (1988) Cyclophosphamide in treatment of minimal change nephrotic syndrome. Eur J Pediatr 147:239–241

    Article  CAS  Google Scholar 

  7. Ueda N, Kuno K, Ito S (1990) Eight and 12 week courses of cyclophosphamide in nephrotic syndrome. Arch Dis Child 65:1147–1150

    Article  CAS  Google Scholar 

  8. Ponticelli C, Edefonti A, Ghio L, Rizzoni G, Rinaldi S, Gusmano R, Lama G, Zacchello G, Confalonieri R, Altieri P, Bettinelli A, Machio G, Cinotu GA, Fuiano G, Schena FP, Castellani A, Della Casa-Alberighi O (1993) Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 8:1326–1332

    CAS  PubMed  Google Scholar 

  9. Kemper MJ, Altrogge H, Ludwig K, Timmermann K, Muller-Wiefel DE (2000) Unfavorable response to cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 14:772–775

    Article  CAS  Google Scholar 

  10. Vester U, Kranz B, Zimmermann S, Hoyer PF (2003) Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook. Pediatr Nephrol 18:661–664

    Article  Google Scholar 

  11. Cammas B, Harambat J, Bertholet-Thomas A, Bouissou F, Morin D, Guigonis V, Bendeddouche S, Afroukh-Hacini N, Cochat P, Llanas B, Decramer S, Ranchin B (2011) Long-term effects of cyclophosphamide therapy in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. Nephrol Dial Transplant 26:178–184

    Article  CAS  Google Scholar 

  12. Hodson EM, Craig JC, Willis NS (2005) Evidence-based management of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 20:1523–1530

    Article  Google Scholar 

  13. Watson AR, Rance CP, Bain J (1985) Long term effects of cyclophosphamide on testicular function. Br Med J Clin Res Ed 291:1457–1460

    Article  CAS  Google Scholar 

  14. International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13:159–165

    Article  Google Scholar 

  15. Berard E, Broyer M, Dehennault M, Dumas R, Eckart P, Fischbach M, Loirat C, Martinat L (2005) Corticosensitive nephrotic syndrome (or nephrosis) in children. Therapeutic guideline proposed by the Pediatric Society of Nephrology. Nephrol Ther 1:150–156

    Article  Google Scholar 

  16. Arbeitsgemeinschaft für Pädiatrische Nephrologie (1982) Effect of cytotoxic drugs in frequently relapsing nephrotic syndrome with and without steroid dependence. N Engl J Med 306:451–454

    Article  Google Scholar 

  17. Garin EH, Pryor ND, Fennell RS III, Richard GA (1978) Pattern of response to prednisone in idiopathic, minimal lesion nephrotic syndrome as a criterion in selecting patients for cyclophosphamide therapy. J Pediatr 92:304–308

    Article  CAS  Google Scholar 

  18. Barratt TM, Cameron JS, Chantler C, Ogg CS, Soothill JF (1973) Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Arch Dis Child 48:286–290

    Article  CAS  Google Scholar 

  19. Yule SM, Boddy AV, Cole M, Price L, Wyllie R, Tasso MJ, Pearson AD, Idle JR (1996) Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 41:13–19

    Article  CAS  Google Scholar 

  20. Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, Krivit W (1980) Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treat Rep 64:1061–1066

    CAS  PubMed  Google Scholar 

  21. Van Husen M, Kemper MJ (2011) New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol doi:https://doi.org/10.1007/s00467-010-1717-5

  22. Fakhouri F, Bocquet N, Taupin P, Presne C, Gagnadoux MF, Landais P, Lesavre P, Chauveau D, Knebelmann B, Broyer M, Grunfeld JP, Niaudet P (2003) Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis 41:550–557

    Article  Google Scholar 

  23. Kabuki N, Okugawa T, Hayakawa H, Tomizawa S, Kasahara T, Uchiyama M (1998) Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome. Pediatr Nephrol 12:467–470

    Article  CAS  Google Scholar 

  24. Kyrieleis HA, Levtchenko EN, Wetzels JF (2007) Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome. Am J Kidney Dis 49:592–597

    Article  CAS  Google Scholar 

  25. Barratt TM, Soothill JF (1970) Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood. Lancet 2:479–482

    Article  CAS  Google Scholar 

  26. International Study of Kidney Disease in Children (1974) Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet 2:423–427

    Google Scholar 

  27. Niaudet P (1992) How to manage a child with steroid-responsive nephrotic syndrome when dose of prednisolone is reduced or when placed on high-dose alternate day steroids. Pediatr Nephrol 6:522

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Nephrology Department, Assistance Publique-Hôpitaux de Paris, Université Paris 7, Hôpital Robert Debré, Paris, France

    Sonia Azib, Marie Alice Macher, Theresa Kwon, Agnes Dechartres, Chantal Loirat, Georges Deschênes & Véronique Baudouin

  2. Clinical Epidemiology Department, Assistance Publique-Hôpitaux de Paris, Université Paris 7, Hôpital Robert Debré, INSERM CIE 5, Paris, France

    Corinne Alberti

Authors
  1. Sonia Azib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie Alice Macher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Theresa Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Agnes Dechartres
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Corinne Alberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chantal Loirat
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Georges Deschênes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Véronique Baudouin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonia Azib.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azib, S., Macher, M.A., Kwon, T. et al. Cyclophosphamide in steroid-dependent nephrotic syndrome. Pediatr Nephrol 26, 927–932 (2011). https://doi.org/10.1007/s00467-011-1830-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-011-1830-0

Keywords

Search

Navigation